Diffuse axonal injury

NurExone Secures Eureka Grant for Collaborative Partnership to Expand to Chronic Spinal Cord Injury Therapy

Retrieved on: 
Wednesday, October 11, 2023
Partnership, Israel Innovation Authority, Cell damage, SCI, Spinal cord, Diffuse axonal injury, Paralysis, Research, Medicine, Inflammation, Cell death, NRX, Patient, IIA, Exosome, NIS, FSE, Pharmaceutical industry, Medical device

The grant is for a collaboration with Canada-based Inteligex Inc. (“Inteligex”) to develop an innovative hybrid therapy tailored for the complex chronic spinal cord injury market.

Key Points: 
  • The grant is for a collaboration with Canada-based Inteligex Inc. (“Inteligex”) to develop an innovative hybrid therapy tailored for the complex chronic spinal cord injury market.
  • Currently, NurExone is in the process of developing the ExoPTEN product specifically for acute spinal cord injuries.
  • This collaborative effort opens the possibility for the Company to expand its focus to chronic spine injuries.
  • Dr. Lior Shaltiel, CEO of NurExone, expressed his excitement about this prestigious grant, stating, “NurExone aims to lead in functional recovery for both acute and chronic segments of the multi-billion-dollar spinal cord injury market.

Nura Bio Initiates Phase I Clinical Trial for its Oral, Brain-Penetrant SARM1 Inhibitor, NB-4746

Retrieved on: 
Friday, August 25, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Senior, Bio, AFL, Traumatic brain injury, Diffuse axonal injury, Pharmacokinetics, ALS, TBI, CIPN, Multiple sclerosis, Doctor of Philosophy, MS, SARM1, Amyotrophy, Safety, Pharmaceutical industry

Nura Bio, Inc. (Nura Bio), a biopharmaceutical company developing neuroprotective, small molecule therapies for the treatment of debilitating neurological diseases, today announced the initiation of the Phase 1 clinical trial of its SARM1 inhibitor, NB-4746.

Key Points: 
  • Nura Bio, Inc. (Nura Bio), a biopharmaceutical company developing neuroprotective, small molecule therapies for the treatment of debilitating neurological diseases, today announced the initiation of the Phase 1 clinical trial of its SARM1 inhibitor, NB-4746.
  • NB-4746 is believed to be a first-in-class, oral, brain-penetrant, neuroprotective SARM1 inhibitor with broad therapeutic potential across diseases of the central, peripheral, and ocular nervous systems.
  • “We are excited about the potential of NB-4746,” said David Lau, PhD, Senior Vice President, Development Sciences, Nura Bio.
  • “The initiation of the Phase 1 trial of NB-4746 marks Nura Bio’s transition to a clinical-stage company,” said Shilpa Sambashivan, PhD, Chief Scientific Officer, Nura Bio.

Clene’s CNM-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light (NfL) levels in the HEALEY ALS Platform Trial

Retrieved on: 
Thursday, June 15, 2023
Neuron, Medicine, File, AFL, CNM, Survival, Diffuse axonal injury, NDA, Biomarker, SALT, LS, Plasma, Risk, SE, Diagnosis, Principal, FDA, ALS, Safety, Pharmaceutical industry, Medical imaging

Surrogate biomarkers such as NfL have recently been used to support an FDA approval for the treatment of ALS.

Key Points: 
  • Surrogate biomarkers such as NfL have recently been used to support an FDA approval for the treatment of ALS.
  • Definite or probable ALS diagnosis per El Escorial criteria (post hoc, n=125); Difference of LS Means on a Ln Scale (SE) = -0.124 (0.054); p=0.023.
  • Higher mortality risk (baseline plasma NfL > median, post hoc, n=79); Difference of LS Means on a Ln Scale (SE) = -0.150 (0.068); p=0.031.
  • Additional biomarker and long-term survival data from the HEALEY ALS Platform Trial double-blind and open-label extension periods have been collected and are undergoing testing preparatory for analysis to be reported later this year.

ZyVersa Therapeutics Announces New Publication in Translational Research Showing IC 100 Reduces Inflammasome Activation in Mouse Model for Alzheimer’s Disease Following Traumatic Brain Injury

Retrieved on: 
Thursday, February 23, 2023
Cognitive neuroscience, Death, Behavior informatics, Inflammasome, Therapy, III, Mouse, NLRP3, University, CDC, Miami Project to Cure Paralysis, Neuron, Structural Damage, Translational research, Administration, Leonard M. Miller School of Medicine, Risk, Paralysis, Publication, Patient, DSM-IV codes, Cell biology, ASC, Associate professor, Inflammation, History, AIM2, Diffuse axonal injury, Neurosurgery, Disability, Translation, Biomedical engineering, Neurology, NLRP1, TBI, Miami, Head injury, Pharmaceutical industry, Medical device, Medicine, Ageing

The article demonstrates that inflammasome activation and pyroptotic release of active cytokines and ASC specks following TBI is synergistic with inflammasome activation that occurs in AD, heightening the inflammatory response and worsening cognitive outcomes.

Key Points: 
  • The article demonstrates that inflammasome activation and pyroptotic release of active cytokines and ASC specks following TBI is synergistic with inflammasome activation that occurs in AD, heightening the inflammatory response and worsening cognitive outcomes.
  • Furthermore, it shows that IC 100, an inflammasome ASC inhibitor, reduces inflammasome activation that triggers the inflammatory response.
  • “We evaluated if blocking inflammasome activity by inhibiting ASC reduces the elevated inflammatory response in AD mice after TBI.
  • “The two publications in Translational Research support the potential of ZyVersa’s proprietary monoclonal antibody inflammasome ASC inhibitor IC 100 in neurological disorders,” stated Stephen Glover, Co-founder, Chairman, CEO, and President of ZyVersa Therapeutics.

Vaccinex, Inc.’s Phase 2 “SIGNAL” Study to Evaluate Pepinemab Antibody in Huntington’s Disease is Published in Nature Medicine along with Detailed Mechanism of Action Study in Journal of Neuroinflammation

Retrieved on: 
Monday, August 8, 2022
People, U.S. Securities and Exchange Commission, Respiration (physiology), GLOBE, Caudate nucleus, SEC, Cancer, Brain, Behavior, Security (finance), Research, HD, Journal of Neuroinflammation, Diffuse axonal injury, Patient, Tumor microenvironment, Astrocyte, Neurodegeneration, Nature Medicine, Microfilament, Immunosuppression, Health, Disease, Government budget balance, HIV disease progression rates, Inflammation, Neuron, Immunoglobulin G, SEMA4D, Kaufman Assessment Battery for Children, Key finding attacks, Apathy, Nasdaq, Locomotion, Forward-looking statement, Microglia, SIGNAL, Caregiver, Neoplasm, Cell, COVID-19, Program, Mutation, Dementia, Atrophy, Cognition, B cell, FDG-PET, Company, Problem solving, Pharmaceutical industry, Medical imaging, Vaccine, Risk management, Journal

ROCHESTER, N.Y., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D), today announced that results of its Phase 2 SIGNAL study to evaluate its SEMA4D-blocking antibody, pepinemab, in patients with Huntington’s Disease (HD) were published in the August 8, 2022 issue of Nature Medicine1, a leading journal for publication of translational and clinical research. In parallel, a second report has been published in the Journal of Neuroinflammation2 detailing the pathologic impact of SEMA4D on neuroinflammatory cells in both HD and Alzheimer’s disease (AD).

Key Points: 
  • These findings encourage continued development of pepinemab as a potential therapy for patients with early manifest symptoms of HD and potentially AD.
  • Accordingly, a phase 1b/2a study of pepinemab in Alzheimers disease has been initiated and is actively enrolling patients (NCT04381468).
  • The mechanism of action of pepinemab, targeting neuroinflammation2, may provide an alternative to other AD therapies that target aggregates of A amyloid.
  • The Nature Medicine publication is available online at https://www.nature.com/articles/s41591-022-01919-8 and Journal of Neuroinflammation at https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-022... ; both articles will also be posted on the Vaccinex website.

OXEIA ANNOUNCES POSITIVE INTERIM RESULTS OF PHASE 2 TRIAL FOR OXE103 FOR THE TREATMENT OF CONCUSSIONS

Retrieved on: 
Wednesday, August 3, 2022
Human, Neuro, Appetite, Brain, Children's Mercy Hospital, Patient, Memory, Concussion, Reactive oxygen species, Diffuse axonal injury, Neurology, GLOBE, Medicine, University of Kansas Medical Center, University, University of San Francisco School of Nursing and Health Professions, Traffic barrier, Ghrelin, Cognition, Pharmaceutical industry, Medical device, Nursing

The trial is focusing on treatment for subjects within 28 days of injury who are highly symptomatic at screening.

Key Points: 
  • The trial is focusing on treatment for subjects within 28 days of injury who are highly symptomatic at screening.
  • This group represents the majority of concussion patients who do not seek treatment immediately following their injury.
  • According to Oxeia CEO, Dr. Michael Wyand, I am encouraged by the interim results we are seeing from the trial.
  • The interim data provide hope for an effective treatment for the millions of people who suffer ongoing post-concussion symptoms due to a lack of effective treatment options.

Americans Fall Short in Concussion Education and Prevention, New Survey Commisioned by Mips Reveals

Retrieved on: 
Thursday, June 2, 2022
National Center for Telehealth & Technology, Korea Disease Control and Prevention Agency, Death, Skiing, Head, Nielsen, Mortality, Concussion, Head Injuries, Centers for Disease Control and Prevention, Tennis, LINK, Brain damage, Sport, Child, Team, Diffuse axonal injury, CDC, Female, FIM, TBI, Center, Male, Risk, Brain, Prevalence, National Center for Health Statistics, Education, Safety, Medical statistics, Sports equipment, Personal protective equipment, Americans, EU, MIPS

STOCKHOLM, June 2, 2022 /PRNewswire/ -- A new survey suggests a large disconnect in Americans' education around concussions and how to reduce the risk of them using helmets.

Key Points: 
  • In the United States, the prevalence of traumatic brain injuries (TBI), especially in sports, has been called a crisis.
  • The survey, which was conducted by Nielsen , a consumer survey company, and commissioned by Mips , a helmet safety technology company, polled a representative sample of 1,000 Americans, split evenly between male and female, ranging 18-65 years old.
  • Among the most significant findings of the survey is that 70 percent of American helmet buyers are unaware of the term rotational motion.
  • Rotational motion is a common cause for concussions and more severe brain injuries in oblique hits to the head.

OXEIA BIOPHARMACEUTICALS ANNOUNCES NEW BOARD AND MANAGEMENT TEAM MEMBERS AND RELOCATES CORPORATE HEADQUARTERS TO BOSTON

Retrieved on: 
Thursday, January 20, 2022
Technology, Accounting, Human, Cognition, University of Kansas Medical Center, Biotechnology, Clinical trial, Memory, D, San Francisco Bay Area, Executive Committee, Diffuse axonal injury, Growth, Concussion, Ghrelin, CEO, Neuro, Mental health, Leg, Leadership, NFL, Infection, Traffic barrier, Kansas City Chiefs, Industry, McClelland, Strategic planning, Therapy, Program, Program management, Deloitte, CFO, Vertex Pharmaceuticals, Brain, University, Board, Awareness, Pharmaceutical industry, Management, Oxeia, Operation, SAN

Joining the Board is Ted Raad, CEO and Board Director at the Massachusetts-based clinical stage biopharmaceutical company, Pulmatrix.

Key Points: 
  • Joining the Board is Ted Raad, CEO and Board Director at the Massachusetts-based clinical stage biopharmaceutical company, Pulmatrix.
  • Concussion R&D continues to be an overlooked medical need despite the growing awareness of a concussion's potential long-term and often debilitating symptoms."
  • In her new role she will be responsible for strategic oversight of the program management and operational functions at Oxeia.
  • Oxeia also announced the recent relocation of its corporate headquarters from San Diego where it was founded to Boston.

PrecisionOS Appoints Five Distinguished Orthopedic Surgeons Specializing in Sports Medicine to Clinical Advisory Board

Retrieved on: 
Tuesday, December 21, 2021
Amon, Schulich School of Medicine & Dentistry, Sport, World Lacrosse, Arizona Cardinals, University, Orthopedic surgery, Arthroscopy, McMaster University, Shoulder, Rehabilitation, Medicine, Arizona Diamondbacks, Hospital for Special Surgery, Diffuse axonal injury, CEO, Medical director, ACL, Virtual reality, Surgeon, Ferry, Education, Associate professor, VR, Olympic Games, Partnership, Hospital, City, Sports medicine, Anterior cruciate ligament injury, Industry, Hip, U.S. Ski & Snowboard, Knee, Department, Associate, Hamilton, Multimedia, Seattle Mariners, Invision, HSS, Knowledge, Dentistry, Medical device, BC, XR

VANCOUVER, BC, Dec. 21, 2021 /PRNewswire/ - PrecisionOS has added five prominent orthopedic surgeons specializing in sports-related injuries to its Clinical Advisory Board.

Key Points: 
  • VANCOUVER, BC, Dec. 21, 2021 /PRNewswire/ - PrecisionOS has added five prominent orthopedic surgeons specializing in sports-related injuries to its Clinical Advisory Board.
  • PrecisionOS develops Virtual Reality (VR) training for residents, practicing surgeons and medical device representatives.
  • The sports medicine surgeons will work with the company to develop advanced orthopedic arthroscopic training in VR.
  • Alan Getgood, M.D., F.R.C.S., is an Associate Professor, Schulich School of Medicine & Dentistry at Fowler Kennedy Sports Medicine Clinic.

Eyevensys Enters Collaboration with Phillips-Medisize and Minnetronix Medical

Retrieved on: 
Monday, September 27, 2021
Technology, Medical Devices, Infectious Diseases, Genetics, Clinical Trials, Software, Biotechnology, Hardware, Health, Optical, Geographic atrophy, Business development, Ciliary muscle, Diffuse axonal injury, Neuro, Pulse generator, Solution, European Medicines Agency, IgG4-related ophthalmic disease, Inflammation, DNA, Device, AMD, Patient, Diabetic retinopathy, Electroporation, NIU, Pulse, Business, Eye, Risk management, Plasmid, VEGF, Retinitis pigmentosa, History, Glaucoma, RF, EMA, Pharmaceutical industry, Vaccine, Medical device, Eyevensys, Minnetronix Medical, EYEVENSYS, MINNETRONIX MEDICAL

Alan Wirbisky, Director of Device Development at Eyevensys, said: The opportunity to collaborate with both Minnetronix Medical and Phillips-Medisize is incredibly significant for Eyevensys given the capabilities and experience that the two companies possess.

Key Points: 
  • Alan Wirbisky, Director of Device Development at Eyevensys, said: The opportunity to collaborate with both Minnetronix Medical and Phillips-Medisize is incredibly significant for Eyevensys given the capabilities and experience that the two companies possess.
  • During our 25 year history, we have successfully partnered with many medical startups like Eyevensys to navigate the pitfalls of electromechanical medical device development.
  • Since 1996, Minnetronix Medical has accelerated medical device breakthroughs via design, development and manufacturing services for companies around the world.
  • Minnetronix Medical is based in St. Paul, Minn. More information can be found on the Minnetronix website, by calling 651-917-4060 or emailing [email protected] .